BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Prezista (Darunavir) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Prezista (Darunavir)\, from ClinicalTrial
 s.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06337032-959@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Prezista (Darunavir): Phase 4 readout est. (NCT06337032)
DESCRIPTION:Prezista (Darunavir)\, phase 4\, HIV.\nStudy: A Study to Provid
 e Continued Access to Study Drug to Children and Adolescents Who Have Comp
 leted Clinical Studies Involving Gilead HIV Treatments\nEstimated primary 
 completion: June 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/darunavir#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06337032
URL:https://assetmemo.bio/drug/darunavir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07792096-959@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Prezista (Darunavir): Phase 3 readout est. (NCT07792096)
DESCRIPTION:Prezista (Darunavir)\, phase 3\, HIV.\nStudy: An Adaptive Platf
 orm Trial for Evaluation of Novel Treatment Regimens in Children and Adole
 scents With HIV in Africa\nEstimated primary completion: June 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/darunavir#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07792096
URL:https://assetmemo.bio/drug/darunavir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
